Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study
- PMID: 28131729
- DOI: 10.1016/j.ijid.2017.01.019
Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study
Abstract
Objectives: Vancomycin is the treatment of choice for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia; however, its use has been subject to scrutiny due to failure in severe infections. Ceftaroline fosamil (CPT-F) is approved for MRSA acute bacterial skin and skin structure infections, but not for bloodstream infections. The clinical outcomes of treatment with CPT-F in patients with MRSA bacteremia were evaluated.
Methods: Patients diagnosed with MRSA bacteremia at Henry Ford Hospital in Detroit, Michigan, USA, involving isolates with a vancomycin minimum inhibitory concentration ≥1.0mg/l and susceptible in vitro to CPT-F, were systematically reviewed retrospectively. Ceftaroline fosamil-treated patients were matched with at least two vancomycin- and/or one daptomycin-treated control patient based on age-patients age 65 years or greater or less than 65 years of age. Outcomes evaluated included the duration of hospitalization, duration of therapy, adverse events, relapse, hospital readmission, and death.
Results: Thirty consecutive cases of MRSA bacteremia treated with CPT-F during the period May 2011 to June 2013 were identified; these patients were matched to 56 MRSA bacteremia patients treated with vancomycin and 46 MRSA bacteremia patients treated with daptomycin. The primary source of MRSA bacteremia in the cohort treated with CPT-F was endocarditis (n=7, 23%), skin/wound (n=9, 30%), and bone/joint (n=8, 27%). The MRSA bacteremia in those treated with CPT-F was community-acquired in 43% of cases, healthcare-associated in 43%, and hospital-acquired in 13%. The mean length of hospital stay for these patients was 22 days. The overall 30-day mortality rate was 13% (n=4) in CPT-F patients versus 24% (n=11) in daptomycin patients and 11% (n=6) in vancomycin patients (p=0.188).
Conclusions: CPT-F demonstrated comparable clinical outcomes in MRSA bacteremia patients compared with the other agents, especially as salvage therapy.
Keywords: Bacteremia; Bloodstream infection; Ceftaroline fosamil; Methicillin-resistant Staphylococcus aureus.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.Antimicrob Agents Chemother. 2016 Sep 23;60(10):5841-8. doi: 10.1128/AAC.00227-16. Print 2016 Oct. Antimicrob Agents Chemother. 2016. PMID: 27431221 Free PMC article. Clinical Trial.
-
Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02483-18. doi: 10.1128/AAC.02483-18. Print 2019 May. Antimicrob Agents Chemother. 2019. PMID: 30858203 Free PMC article. Clinical Trial.
-
Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care.Int J Antimicrob Agents. 2021 Apr;57(4):106310. doi: 10.1016/j.ijantimicag.2021.106310. Epub 2021 Feb 18. Int J Antimicrob Agents. 2021. PMID: 33609718
-
Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches.Infect Dis Clin North Am. 2020 Dec;34(4):849-861. doi: 10.1016/j.idc.2020.04.003. Epub 2020 Sep 30. Infect Dis Clin North Am. 2020. PMID: 33011050 Review.
-
Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches.Infect Dis Clin North Am. 2016 Jun;30(2):491-507. doi: 10.1016/j.idc.2016.02.009. Infect Dis Clin North Am. 2016. PMID: 27208769 Review.
Cited by
-
Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study.Drugs Real World Outcomes. 2024 Jun;11(2):273-283. doi: 10.1007/s40801-024-00422-5. Epub 2024 Apr 2. Drugs Real World Outcomes. 2024. PMID: 38564101 Free PMC article.
-
New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.J Clin Med. 2023 Dec 14;12(24):7693. doi: 10.3390/jcm12247693. J Clin Med. 2023. PMID: 38137762 Free PMC article. Review.
-
Antimicrobial resistance in methicillin-resistant Staphylococcus aureus to newer antimicrobial agents.Antimicrob Agents Chemother. 2019 Sep 9;63(12):e01216-19. doi: 10.1128/AAC.01216-19. Epub 2019 Sep 16. Antimicrob Agents Chemother. 2019. PMID: 31527033 Free PMC article. Review.
-
The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00468-20. doi: 10.1128/AAC.00468-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32312776 Free PMC article. Review.
-
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research.Nat Rev Microbiol. 2019 Apr;17(4):203-218. doi: 10.1038/s41579-018-0147-4. Nat Rev Microbiol. 2019. PMID: 30737488 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical